Dalotuzumab
- Product Name
- Dalotuzumab
- CAS No.
- 1005389-60-5
- Chemical Name
- Dalotuzumab
- Synonyms
- Dalotuzumab;Dalotuzumab (anti-IGF1R);Research Grade Dalotuzumab;Research Grade Dalotuzumab(DHC29901)
- CBNumber
- CB18080814
- Formula Weight
- 0
- MOL File
- Mol file
Dalotuzumab Property
- form
- Liquid
- color
- Colorless to light yellow
Dalotuzumab Chemical Properties,Usage,Production
Uses
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo[1][2][3].
in vivo
Dalotuzumab (h7C10; i.p.; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days) shows anti-tumor effects on MCF-7 and A549 xenograft tumor models[1].
| Animal Model: | Swiss Nude mice (MCF-7 and A549 xenograft tumor models)[1]. |
| Dosage: | 125 and 250 (first time) μg/mice |
| Administration: | Intraperitoneal injection; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days |
| Result: | Led to average tumor volume at 6 weeks post-cell injection was reduced by 70% and 72% in the MCF-7 and A549 models, respectively. |
References
[1] Goetsch L, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005 Jan 10;113(2):316-28. DOI:10.1002/ijc.20543
[2] Bitelman C, et al. IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett. 2013 Jul 10;335(1):153-9. DOI:10.1016/j.canlet.2013.02.009
[3] Scartozzi M, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010 Jun;12(3):361-71. PMID:20521225
Dalotuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Dalotuzumab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 0513-66337626 18051384581
- sales@chemhifuture.com
- Country
- China
- ProdList
- 5929
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
- Tel
- 0731-13823398 15111215862
- 313359644@qq.com
- Country
- China
- ProdList
- 4161
- Advantage
- 58
- Tel
- 0573-83568680 18057391398
- 3956524501@qq.com
- Country
- China
- ProdList
- 1442
- Advantage
- 58